Alan G. White
Education
Ph.D., economics, University of British Columbia; M. Litt., economics and B.A., economics and mathematics, University of Dublin, Trinity College
Summary of Experience
Dr. White specializes in health care, transfer pricing and valuation, and general commercial litigation. He combines his expertise in applied microeconomics, statistics, and econometrics with nearly 25 years of experience with client engagements. A diverse range of clients have retained Dr. White to assist in all stages of the litigation cycle – including advising on discovery issues, expert report preparation, and preparation for deposition and trial. He has worked on general commercial litigation matters such as allegations of false advertising and breach of contract, investigations into alleged off-label promotion of prescription drugs, and the economic impact of generic drug entry/substitution. Additionally, he has also analyzed economic issues relevant to class certification and quantification of damages.
Dr. White has managed numerous commercial litigation matters, supporting academic and industry specialists with expertise in industrial organization, statistics, health economics, and marketing. His tax and transfer pricing work has evaluated the arm’s length nature of pricing in intercompany transactions, and the estimation of useful economic lives for various tangible and intangible assets. In addition to his litigation work, Dr. White’s health economics engagements have included the development of empirical models for evaluating factors to help identify patients at risk of prescription opioid abuse, as well as the estimation of societal economic costs of prescription opioid abuse.
An active researcher, Dr. White’s publications have focused on specific health economics issues, such as the economics of prescription opioid abuse and the evaluation of the impact of biosimilar approval on the litigation landscape. He has presented and participated in a number of industry conferences. Dr. White is an adjunct faculty member in the Department of Economics at Northeastern University, where he teaches courses on applied microeconomics and applied econometrics.
- Amazon, Inc. & Subsidiaries v. Commissioner of Internal Revenue
- AstraZeneca v. TAP Pharmaceuticals, Inc.
- BTG International Inc v Wellstat Therapeutics Corporation
- Economic Burden of Opioid Abuse
- GlaxoSmithKline Holdings (Americas) Inc. v. Commissioner of the IRS
- Kwaak et al v. Pfizer Inc.
- Louisiana Wholesale Drug Co., Inc. v. Sanofi-Aventis
- Mylan Pharmaceuticals v. Procter & Gamble Co.
- V. Ross Morrison v. Her Majesty the Queen
-
Prescription Opioid Utilization Patterns, and Associated Outcomes, among Privately-Insured Patients Prescribed Opioids to Manage Pain Associated with Osteoarthritis
Current Medical Research and Opinion, 2023
2023Schepman P, Rice JB, Beck CG, White A, Robinson RL, Thakkar S, Fernan C, Emir B, Silverman S
-
Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome
Current Medical Research and Opinion, 2021
2021Rice JB, Panaccio MP, White A, Simes M, Billmyer E, Downes N, Niewoehner J, Wan GJ
-
Assessment of Work Loss Associated With Prescription-Related Opioid Use Disorder: A Retrospective Analysis of Claims Data
Journal of Occupational and Environmental Medicine, 2020
2020White AG, Spittle T, Fernan C, Billmyer E, Marrett E, Kwong WJ, Rossiter LF
-
Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
Ocular Immunology and Inflammation, 2020
2020Albini TA, Rice JB, White AG, Johnson M, Reiff J, Lima AF, Bartels-Peculis L, Ciepielewska G, Nelson WW
-
Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis
Neurology and Therapy, 2020
2020Rice JB, Panaccio MP, White A, Simes M, Billmyer E, Downes N, Niewoehner J, Wan GJ
-
Modeling the potential impact of abuse-deterrent opioids on medical resource utilization
Journal of Medical Economics, 2019
2019Yenikomshian MA, White AG, Carson ME, Jia ZB, Mendoza MR, Roland CL
-
Predictors of High-cost Patients With Noninfectious Inflammatory Eye Diseases
Clinical Therapeutics, 2019
2019Nelson WW, Rice JB, White AG, Johnson M, Reiff J, Lima AF, Bartels-Peculis L, Ciepielewska G, Albini TA
-
Survey evidence to evaluate a marketing claim: Skye Astiana, Plaintiff v. Ben & Jerry's Homemade, Inc., Defendant
Handbook of Marketing Analytics: Methods and Applications in Marketing Management, Public Policy, and Litigation Support
2018 -
Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population
Journal of Medical Economics. 2018 Sep;21(9):846-852
2018Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW
-
Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population
Current Medical Research and Opinion. 2018 Aug;34(8):1519-1527
2018Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW
-
Survey evidence to evaluate a marketing claim: Skye Astiana, Plaintiff v. Ben & Jerry's Homemade, Inc., Defendant
Handbook of Marketing Analytics: Methods and Applications in Marketing Management, Public Policy, and Litigation Support
2018 -
Smart Contracts & Their Potential Tax Implications
Lawyer Monthly, October 24, 2018
2018 -
The burden of non-infectious intraocular inflammatory eye diseases: a systematic literature review
Current Medical Research and Opinion. 2018 Dec;34(12):2095-2103
2018 -
Economic burden of sarcoidosis in a commercially-insured population in the United States
Journal of Medical Economics. Oct 2017;20(10):1048-1055
2017Rice JB, White A, Lopez A, Conway A, Wagh A, Nelson WW, Philbin M, Wan GJ
-
High-cost sarcoidosis patients in the United States: Patient characteristics and patterns of health care resource utilization
Journal of Managed Care and Specialty Pharmacy. 2017;23(12):1261-1269a
2017 -
The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States
Current Medical Research and Opinion. Aug 2017;33(8):1473-1480
2017Rice JB, White AG, Galebach P, Korenblat KM, Wagh A, Lovelace B, Wan GJ, Jamil K
-
Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review
Clinical Therapeutics. Nov 2017;39(11):2216-2229
2017 -
Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients
Journal of Opioid Management. Sep/Oct 2017;13(5):291-301
2017Yenikomshian MA, White AG, Carson ME, Garrison LP, Oderda GM, Biskupiak JE, Hlavacek PR, Roland CL
-
The Potential For Litigation In New Era Of Biosimilars
Law360, September 20, 2016
2016Frois C, Mortimer R, White A
-
Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population
Journal of Medical Economics, 2016 07; 19(7): 649-654
2016Rice BJ, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M.
-
A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids
Journal of Pain, 2016
2016White A, Yenikomshian M, Carson M, Masters E, Roland C
-
Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs
J Opioid Manag. 2015 May-Jun;11(3):199-210
2015White AG, LeCates J, Birnbaum HG, Cheng W, Roland CL, Mardekian J
-
Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States
Pain Med. 2014 Sep;15(9):1450-4. doi: 10.1111/pme.12489. Epub 2014 Jul 8
2014Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Rossiter LF, Michna E
-
Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States
Pain Medicine 2011; 12: 657-667
2011Birnbaum H, White A, Schiller M, Waldman T, Cleveland J, Roland C
-
Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction
Appl Health Econ Health Policy. 2009;7(1):61-70
2009White A, Birnbaum HG, Rothman D, Katz N
-
Analytic models to identify patients at risk for prescription opioid abuse
Am J Manag Care. 2009 Dec;15(12):897-906
2009White A, Birnbaum H, Shiller M, Tang J, Katz N
-
Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States.
J Occup Environ Med 2008 Sep;50(9):998-1005.
2008White A, Birnbaum HG, Janagap C, Buteau S, Schein J
-
Estimated Costs of Prescription Opioid Analgesic Abuse in the United States in 2001: A Societal Perspective.
Clin J Pain 2006 Oct;22(8):667-76
2006Birnbaum H, White A, Reynolds J, Greenberg P, Zhang M, Vallow S, Schein J, Katz N
-
Hedonic Price Indexes for Personal Computer Operating Systems and Productivity Suites
Annales d’Economie et de Statistique, 2005; No. 79/80: 787-807, previously issued as NBER Working Paper, No. 10427, April 2004
2004White A, Berndt E, Abel J
-
Outlet types and the Canadian Consumer Price Index
Canadian Journal of Economics, 2000, 33 (2):488-505
2000 -
Measurement Biases in Consumer Price Indexes
International Statistical Review, 1999; 67 (3):311–325
1999